Breakthrough FDA Approval Secured By This Medical Company For Depressive Disorder

In a significant development for the mental health industry, Cybin Inc., an innovative biopharmaceutical company focused on psychedelic therapeutics, has announced two major breakthroughs. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to their novel psychedelic molecule, CYB003, and they have also released positive four-month durability data for the treatment of Major Depressive Disorder (MDD). $Cybin(CYBN.US)$